{"id":"selective-therapy-drug","safety":{"commonSideEffects":[{"rate":null,"effect":"Unknown"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This approach allows for precise control over the drug's effects, reducing off-target interactions and improving efficacy.","oneSentence":"Selective therapy targets the drug's molecular mechanism to modulate its activity.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:37:34.686Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Various conditions"}]},"trialDetails":[{"nctId":"NCT05432804","phase":"PHASE1, PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-20","conditions":"MGMT-Methylated Glioblastoma, Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated Glioblastoma","enrollment":97},{"nctId":"NCT07388563","phase":"PHASE1","title":"Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Lymphoma, T Cell, Peripheral, T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma","enrollment":20},{"nctId":"NCT06998407","phase":"PHASE1, PHASE2","title":"ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Avenzo Therapeutics, Inc.","startDate":"2025-08-20","conditions":"HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer","enrollment":380},{"nctId":"NCT05099003","phase":"PHASE1, PHASE2","title":"A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-05-31","conditions":"Malignant Glioma","enrollment":132},{"nctId":"NCT07487467","phase":"NA","title":"Autologous SVF Therapy for Type 2 Diabetes","status":"RECRUITING","sponsor":"Kaiser Clinic and Hospital","startDate":"2025-01-20","conditions":"Diabetes Mellitus, Type 2","enrollment":10},{"nctId":"NCT05217498","phase":"PHASE1, PHASE2","title":"Combining Low Oxygen Therapy and an Adenosine A2a Receptor Antagonist to Improve Functional Mobility After Spinal Cord Injury","status":"NOT_YET_RECRUITING","sponsor":"Randy Trumbower, PT, PhD","startDate":"2027-09-01","conditions":"Spinal Cord Injuries, Myelopathy","enrollment":40},{"nctId":"NCT07340541","phase":"PHASE2","title":"Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies","status":"NOT_YET_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2026-02","conditions":"Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer","enrollment":700},{"nctId":"NCT07484113","phase":"PHASE1","title":"IL6-receptor Inhibitor Iwith Belumosudil for the Treatment of Belumosudil-refractory cGVHD","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2026-05","conditions":"cGVHD","enrollment":10},{"nctId":"NCT06152809","phase":"PHASE1","title":"CIML NK Cells With Venetoclax for AML","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-02-20","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Recurrent, Leukemia","enrollment":10},{"nctId":"NCT05098132","phase":"PHASE1, PHASE2","title":"Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers","status":"RECRUITING","sponsor":"Synthekine","startDate":"2022-01-25","conditions":"Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC","enrollment":364},{"nctId":"NCT04443088","phase":"PHASE1","title":"An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Shenzhen Ionova Life Sciences Co., Ltd.","startDate":"2020-06-26","conditions":"Cancer, Solid Tumor, Adult, Cancer Metastatic","enrollment":78},{"nctId":"NCT06993844","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Ensem Therapeutics","startDate":"2025-06-10","conditions":"Advanced Solid Tumors, Advanced Breast Cancer","enrollment":233},{"nctId":"NCT02998268","phase":"PHASE2","title":"Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2017-03-07","conditions":"Esophageal Adenocarcinoma","enrollment":42},{"nctId":"NCT06075953","phase":"PHASE2","title":"DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2024-02-17","conditions":"Ductal Carcinoma in Situ","enrollment":400},{"nctId":"NCT04588922","phase":"PHASE1, PHASE2","title":"Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML","status":"RECRUITING","sponsor":"Sellas Life Sciences Group","startDate":"2021-05-10","conditions":"Hematologic Malignancies","enrollment":160},{"nctId":"NCT03947216","phase":"PHASE2","title":"Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2020-10-23","conditions":"Parkinson Disease","enrollment":117},{"nctId":"NCT06332508","phase":"PHASE1","title":"Pulsed Electromagnetic Fields (PEMFs) - A Highly Selective Breast CAncer Treatment pLatform (PASCAL)","status":"COMPLETED","sponsor":"National University Hospital, Singapore","startDate":"2022-12-30","conditions":"Breast Cancer","enrollment":14},{"nctId":"NCT06559306","phase":"PHASE3","title":"Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-07-25","conditions":"Depressive Disorder, Major","enrollment":752},{"nctId":"NCT06382948","phase":"PHASE3","title":"Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.","status":"RECRUITING","sponsor":"MedSIR","startDate":"2024-12-05","conditions":"Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":240},{"nctId":"NCT07078604","phase":"PHASE2","title":"A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-11","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":20},{"nctId":"NCT07465913","phase":"PHASE4","title":"Rocklatan vs Latanoprost Post-DSLT","status":"NOT_YET_RECRUITING","sponsor":"Eye Centers of Southeast Texas","startDate":"2026-05-06","conditions":"Glaucoma","enrollment":36},{"nctId":"NCT06218303","phase":"PHASE1","title":"Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ","status":"RECRUITING","sponsor":"Finn, Olivera, PhD","startDate":"2024-02-07","conditions":"Ductal Carcinoma in Situ","enrollment":50},{"nctId":"NCT04838769","phase":"NA","title":"REZŪM vs. Dual Drug Therapy for Symptomatic Benign Prostatic Hyperplasia in Sexually Active Men","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Scientific Corporation","startDate":"2021-09-15","conditions":"Benign Prostatic Hyperplasia (BPH)","enrollment":154},{"nctId":"NCT07452341","phase":"NA","title":"Effect of Virtual Reality on Depression in Adolescent Females","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2026-08-01","conditions":"Depression","enrollment":48},{"nctId":"NCT04179864","phase":"PHASE1, PHASE2","title":"A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer","status":"TERMINATED","sponsor":"Epizyme, Inc.","startDate":"2019-11-18","conditions":"Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer","enrollment":102},{"nctId":"NCT07020221","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors","status":"RECRUITING","sponsor":"Verastem, Inc.","startDate":"2025-06-24","conditions":"Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer","enrollment":295},{"nctId":"NCT07458022","phase":"PHASE2","title":"MAGNESIUM & SSRI VS SSRI ALONE AMONG PATIENTS OF MAJOR DEPRESSIVE DISORDER","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Child Health Sciences and Children's Hospital, Lahore","startDate":"2025-12-01","conditions":"Major Depressive Diorder","enrollment":50},{"nctId":"NCT07333053","phase":"NA","title":"Clinical Efficacy of Transarterial Infusion Chemotherapy for Unresectable Colorectal Cancer","status":"RECRUITING","sponsor":"Quanda Liu","startDate":"2026-03-31","conditions":"Unresectable Colorectal Cancer","enrollment":30},{"nctId":"NCT05362292","phase":"PHASE4","title":"TReating Incontinence for Underlying Mental and Physical Health","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2022-10-04","conditions":"Urinary Incontinence, Urge, Urinary Incontinence, Overactive Bladder","enrollment":270},{"nctId":"NCT05679401","phase":"PHASE3","title":"A Study With Imlifidase in Anti-GBM Disease","status":"TERMINATED","sponsor":"Hansa Biopharma AB","startDate":"2022-12-22","conditions":"Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease, Goodpasture Syndrome","enrollment":50},{"nctId":"NCT07139834","phase":"PHASE1","title":"Pattern Separation in Major Depressive Disorder","status":"NOT_YET_RECRUITING","sponsor":"Jeffrey Miller","startDate":"2026-04","conditions":"Major Depressive Disorder (MDD)","enrollment":30},{"nctId":"NCT07447271","phase":"NA","title":"Ultrasound Guided Cervical Selective Nerve Root Block Versus Fluoroscopic Guided Cervical Transforaminal Epidural Block","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pusan National University Yangsan Hospital","startDate":"2025-12-22","conditions":"Cervical Radiculopathy","enrollment":330},{"nctId":"NCT06481241","phase":"NA","title":"Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-06-10","conditions":"Philadelphia Chromosome Negative ALL, Acute Lymphoblastic Leukemia, Adult","enrollment":77},{"nctId":"NCT05768139","phase":"PHASE1, PHASE2","title":"First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2023-04-17","conditions":"Breast Cancer, Solid Tumors, Adult","enrollment":720},{"nctId":"NCT07438106","phase":"PHASE2","title":"A Phase III Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-02","conditions":"Locally Advanced Pancreatic Cancer With KRAS G12D Mutation","enrollment":30},{"nctId":"NCT04764942","phase":"PHASE1, PHASE2","title":"Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2021-05-06","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":39},{"nctId":"NCT05438420","phase":"PHASE1, PHASE2","title":"Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Qurient Co., Ltd.","startDate":"2023-01-12","conditions":"Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer","enrollment":120},{"nctId":"NCT07431060","phase":"NA","title":"Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis","status":"RECRUITING","sponsor":"West China Second University Hospital","startDate":"2026-02-13","conditions":"Langerhans Cell Histiocytosis (LCH)","enrollment":120},{"nctId":"NCT04059484","phase":"PHASE2","title":"Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-10-22","conditions":"Breast Cancer Metastatic","enrollment":367},{"nctId":"NCT05448755","phase":"PHASE2","title":"A Study of ELX-02 in Patients With Alport Syndrome","status":"COMPLETED","sponsor":"Eloxx Pharmaceuticals, Inc.","startDate":"2022-11-28","conditions":"Alport Syndrome","enrollment":3},{"nctId":"NCT07209267","phase":"PHASE2","title":"Baricitinib Curative Repression of HIV-1","status":"NOT_YET_RECRUITING","sponsor":"Emory University","startDate":"2026-03","conditions":"HIV Infection, HIV","enrollment":20},{"nctId":"NCT06016387","phase":"PHASE2","title":"Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2023-11-25","conditions":"HER2-positive Breast Cancer, LMD","enrollment":30},{"nctId":"NCT06049797","phase":"","title":"A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2023-11-15","conditions":"Hot Flashes","enrollment":999},{"nctId":"NCT07418034","phase":"PHASE2","title":"A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)","status":"NOT_YET_RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2026-05","conditions":"Head and Neck Cancer, Head and Neck Squamous Cell Cancer, Head and Neck Squamous Cell Carcinoma","enrollment":132},{"nctId":"NCT06459869","phase":"PHASE1","title":"NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Akamis Bio","startDate":"2025-04-07","conditions":"Locally Advanced Rectal Cancer (LARC)","enrollment":30},{"nctId":"NCT06573970","phase":"PHASE4","title":"Atomoxetine and Executive Function in PTSD","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-04-01","conditions":"Posttraumatic Stress Disorder With Attention Defic","enrollment":160},{"nctId":"NCT07405229","phase":"PHASE4","title":"MEdical Treatment in Idiopathic Ventricular Fibrillation Patients","status":"RECRUITING","sponsor":"Bo Gregers Winkel","startDate":"2018-05-01","conditions":"Idiopathic Ventricular Fibrillation, Cardiac Arrest, Out-Of-Hospital","enrollment":218},{"nctId":"NCT07130955","phase":"NA","title":"A Randomized Trial of Six-Channel RF Ablation System for Renal Denervation in Uncontrolled Hypertension and Chronic Kidney Disease","status":"ENROLLING_BY_INVITATION","sponsor":"Shanghai Golden Leaf MedTec Co. Ltd","startDate":"2025-08-08","conditions":"Hypertension, CKD - Chronic Kidney Disease","enrollment":236},{"nctId":"NCT04183205","phase":"PHASE4","title":"Predicting SSRI Efficacy in Veterans With PTSD","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2019-09-11","conditions":"Posttraumatic Stress Disorder, Major Depressive Disorder","enrollment":26},{"nctId":"NCT07255638","phase":"","title":"A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany","status":"RECRUITING","sponsor":"Blueprint Medicines Corporation","startDate":"2025-12-09","conditions":"Indolent Systemic Mastocytosis","enrollment":80},{"nctId":"NCT05412082","phase":"PHASE1","title":"SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"University of Miami","startDate":"2022-10-05","conditions":"Locally Advanced Rectal Cancer","enrollment":25},{"nctId":"NCT06997198","phase":"PHASE4","title":"Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities","status":"NOT_YET_RECRUITING","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2026-03-01","conditions":"Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities","enrollment":25},{"nctId":"NCT07332247","phase":"PHASE2","title":"PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-03","conditions":"Nasopharangeal Cancer, Recurrent Nasopharynx Carcinoma","enrollment":94},{"nctId":"NCT06313203","phase":"PHASE2","title":"HAI-Floxuridine, or SIRT, Combined With Gemox For Patients With Intra-Hepatic Cholangiocarcinoma Not Amenable to Resection (TOMCAT)","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2024-02-13","conditions":"Intrahepatic Cholangiocarcinoma, Chemotherapy Effect","enrollment":39},{"nctId":"NCT05621759","phase":"PHASE2","title":"Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2022-09-07","conditions":"Graft Vs Host Disease","enrollment":27},{"nctId":"NCT07372352","phase":"PHASE2","title":"Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-01-15","conditions":"Peripheral T Cells Lymphoma (PTCL)","enrollment":26},{"nctId":"NCT07172958","phase":"PHASE1","title":"Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)","status":"RECRUITING","sponsor":"Children's National Research Institute","startDate":"2026-01-27","conditions":"Rhabdomyosarcoma, Ewing Sarcoma, Neuroblastoma","enrollment":18},{"nctId":"NCT06239272","phase":"PHASE1, PHASE2","title":"NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-03-27","conditions":"Adipocytic Neoplasm, Liposarcoma, Atypical Fibroxanthoma","enrollment":139},{"nctId":"NCT04216329","phase":"PHASE1","title":"Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-07","conditions":"Gliosarcoma, Newly Diagnosed, Glioblastoma","enrollment":11},{"nctId":"NCT07357987","phase":"PHASE3","title":"Intra-arterial Tenecteplase for Acute Medium Vessel Occlusion Stroke","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2026-01-22","conditions":"Ischemic Stroke, Medium Vessel Occlusion, Tenecteplase","enrollment":488},{"nctId":"NCT07222215","phase":"PHASE2","title":"PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)","status":"RECRUITING","sponsor":"Kristina A. Fanucci","startDate":"2026-01-16","conditions":"Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer, Breast Cancer","enrollment":297},{"nctId":"NCT05528224","phase":"NA","title":"Effect of SC-ICBT for Adults With OCD：A Three-Arm Randomized Controlled Trial","status":"TERMINATED","sponsor":"Shanghai Mental Health Center","startDate":"2022-09-01","conditions":"Obsessive-Compulsive Disorder","enrollment":46},{"nctId":"NCT07320508","phase":"PHASE2","title":"Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective Study","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2026-01-20","conditions":"Adenoid Cystic Carcinoma, Sinonasal Carcinoma, Epirubicin","enrollment":100},{"nctId":"NCT07353294","phase":"PHASE1","title":"Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2026-01-01","conditions":"Bladder Urothelial Carcinoma, Lymph Node Metastasis","enrollment":12},{"nctId":"NCT05569759","phase":"PHASE2","title":"A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)","status":"COMPLETED","sponsor":"Kezar Life Sciences, Inc.","startDate":"2023-05-23","conditions":"Autoimmune Hepatitis","enrollment":24},{"nctId":"NCT05826964","phase":"PHASE2","title":"Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2023-06-12","conditions":"Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":24},{"nctId":"NCT06076837","phase":"PHASE1","title":"The Seven Trial: Exploiting the Unfolded Protein Response","status":"ACTIVE_NOT_RECRUITING","sponsor":"HonorHealth Research Institute","startDate":"2025-01-09","conditions":"Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic","enrollment":6},{"nctId":"NCT07328373","phase":"","title":"Neurobiological and Genomic Predictors of Relapse in Depression","status":"RECRUITING","sponsor":"Mehmet Kemal Arikan","startDate":"2025-01-01","conditions":"Healthy, Major Depressive Disorder (MDD)","enrollment":204},{"nctId":"NCT02069730","phase":"NA","title":"A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2014-06","conditions":"Salivary Gland Cancer, Metastatic, Advanced","enrollment":114},{"nctId":"NCT04221503","phase":"PHASE2","title":"Niraparib/TTFields in GBM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2019-12-30","conditions":"Glioblastoma, Recurrent Glioblastoma, GBM","enrollment":30},{"nctId":"NCT06043674","phase":"PHASE2","title":"Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation","status":"RECRUITING","sponsor":"Christine Ryan","startDate":"2024-01-22","conditions":"Chronic Lymphocytic Leukemia, Richter's Transformation","enrollment":70},{"nctId":"NCT07318805","phase":"PHASE1","title":"A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-12-16","conditions":"Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer","enrollment":260},{"nctId":"NCT05387512","phase":"","title":"A Real World Study of β2-Adrenergic Blocker Plus PD-1 Inhibitor in Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Affiliated Hospital of Nantong University","startDate":"2022-01-12","conditions":"Lung Cancer","enrollment":59},{"nctId":"NCT05955326","phase":"PHASE4","title":"Study to Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke","status":"RECRUITING","sponsor":"Pharmazz, Inc.","startDate":"2024-01-08","conditions":"Acute Cerebral Ischemia","enrollment":160},{"nctId":"NCT07310719","phase":"NA","title":"A Comparative Study of Intraocular Pressure Control Using Selective Laser Trabeculoplasty and Latanoprost as Initial Treatments for Primary Open Angle Glaucoma and Ocular Hypertension in Lagos State University Teaching Hospital","status":"RECRUITING","sponsor":"Lagos State Health Service Commission","startDate":"2025-10-15","conditions":"Primary Open Angle Glaucoma or Ocular Hypertension","enrollment":138},{"nctId":"NCT04648254","phase":"PHASE1","title":"Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor","status":"COMPLETED","sponsor":"Qurient Co., Ltd.","startDate":"2020-11-18","conditions":"Solid Tumor, Advanced Cancer, Metastatic Cancer","enrollment":51},{"nctId":"NCT07300852","phase":"NA","title":"DSLT in Normal Tension Glaucoma (NTG) Asian Eyes","status":"NOT_YET_RECRUITING","sponsor":"Ngoc Nguyen Inc.","startDate":"2026-01-01","conditions":"Normal Tension Glaucoma (NTG), Glaucoma, Open Angle Glaucoma (OAG)","enrollment":40},{"nctId":"NCT03161431","phase":"PHASE1","title":"SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Syntrix Biosystems, Inc.","startDate":"2019-06-12","conditions":"Melanoma Stage III, Melanoma Stage IV","enrollment":77},{"nctId":"NCT07296705","phase":"PHASE2","title":"Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC","status":"RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2025-10-25","conditions":"Muscle Invasive Bladder Cancer (MIBC)","enrollment":25},{"nctId":"NCT07294495","phase":"NA","title":"Effect of Henagliflozin on Myocardial Fibrosis in Non-Obstructive HCM: A Randomized, Double-Blind, Placebo-Controlled Trial Using 68Ga/18F-FAPI PET/CMR","status":"NOT_YET_RECRUITING","sponsor":"Shanghai East Hospital","startDate":"2026-01-07","conditions":"HCM - Hypertrophic Cardiomyopathy","enrollment":150},{"nctId":"NCT07293468","phase":"PHASE2, PHASE3","title":"Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)","status":"RECRUITING","sponsor":"Tuen Mun Hospital","startDate":"2024-04-01","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":106},{"nctId":"NCT05171166","phase":"PHASE2, PHASE3","title":"Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.","status":"TERMINATED","sponsor":"Peking University","startDate":"2021-12-24","conditions":"Hepatocellular Carcinoma","enrollment":18},{"nctId":"NCT06387121","phase":"PHASE2","title":"Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-04-02","conditions":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","enrollment":53},{"nctId":"NCT01639508","phase":"PHASE2","title":"Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-07","conditions":"Non-Small Cell Lung Cancer","enrollment":86},{"nctId":"NCT06433635","phase":"PHASE4","title":"Sequential Multiple Assignment Randomized Trial for Bipolar Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-10-01","conditions":"Bipolar I Disorder, Depression","enrollment":2726},{"nctId":"NCT07282262","phase":"PHASE2","title":"An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-05-01","conditions":"Biliary Tract Cancer","enrollment":300},{"nctId":"NCT05561361","phase":"","title":"The Effect of SAAE on Vascular Endothelial Function in PA Patients","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2022-10-01","conditions":"Primary Aldosteronism","enrollment":200},{"nctId":"NCT06922591","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients","status":"RECRUITING","sponsor":"Tango Therapeutics, Inc.","startDate":"2025-05-31","conditions":"PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC","enrollment":183},{"nctId":"NCT06107868","phase":"PHASE1","title":"Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2024-03-20","conditions":"Recurrent Ovarian Cancer, Recurrent Uterine Cancer, Metastatic Cancer","enrollment":6},{"nctId":"NCT07246278","phase":"PHASE1, PHASE2","title":"Celecoxib in Parkinson Disease as Adjuvant Therapy","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-11-20","conditions":"Parkinson Disease","enrollment":80},{"nctId":"NCT06421948","phase":"PHASE1, PHASE2","title":"Linperlisib Combined With Chidamide in Patients With PTCL","status":"RECRUITING","sponsor":"Yanyan Liu","startDate":"2024-05-25","conditions":"Peripheral T-cell Lymphoma","enrollment":134},{"nctId":"NCT07267286","phase":"PHASE2","title":"Tirellizumab Combined With TP Neoadjuvant Therapy in the Treatment of Early Oral Squamous Cell Carcinoma （HNC-SYSU-005）","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-12-15","conditions":"HNSCC, PD-1","enrollment":60},{"nctId":"NCT07239011","phase":"PHASE1, PHASE2","title":"Dapagliflozin in Depression","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-11-01","conditions":"Depression","enrollment":60},{"nctId":"NCT07242612","phase":"NA","title":"Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis","status":"RECRUITING","sponsor":"Khyber Medical University Peshawar","startDate":"2025-10-01","conditions":"Osteoporosis, Osteoporosis, Postmenopausal","enrollment":40},{"nctId":"NCT05867251","phase":"PHASE1, PHASE2","title":"Study of AVZO-021 in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Avenzo Therapeutics, Inc.","startDate":"2023-08-30","conditions":"Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer","enrollment":430},{"nctId":"NCT03393013","phase":"PHASE1, PHASE2","title":"A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis","status":"COMPLETED","sponsor":"Kezar Life Sciences, Inc.","startDate":"2018-02-20","conditions":"Lupus Nephritis, Systemic Lupus Erythematosus","enrollment":69},{"nctId":"NCT04844970","phase":"PHASE2","title":"Anamorelin Study for Advanced Pancreatic Cancer","status":"TERMINATED","sponsor":"Lahey Clinic","startDate":"2023-04-01","conditions":"Metastatic Pancreatic Cancer","enrollment":4},{"nctId":"NCT05400122","phase":"PHASE1","title":"Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer","status":"SUSPENDED","sponsor":"David Wald","startDate":"2022-09-09","conditions":"Colorectal Cancer, Hematologic Malignancy, Rectum Cancer","enrollment":12},{"nctId":"NCT06088381","phase":"PHASE2","title":"Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)","status":"RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2024-03-07","conditions":"Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Oropharynx Cancer","enrollment":61},{"nctId":"NCT04925375","phase":"PHASE2","title":"Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2021-07-14","conditions":"Interstitial Lung Disease, Common Variable Immunodeficiency","enrollment":38}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":124,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Selective Therapy: Drug","genericName":"Selective Therapy: Drug","companyName":"Vanderbilt University Medical Center","companyId":"vanderbilt-university-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Selective Therapy is a treatment approach that has been studied in various clinical trials for conditions such as depression, epilepsy, and fibromyalgia. The treatment involves a combination of interventions, including cognitive behavioral therapy and physiotherapy protocol, but the specific medication or therapy used is not specified in the available information.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}